Kenneth Hoberman

Kenneth Hoberman

Chief Operating Officer at STEMLINE THERAPEUTICS, INC.

Net worth: 19 M $ as of 30/09/2026

61 year
Health Technology
Consumer Services
Commercial Services

Profile

Mr. Kenneth Hoberman is an Independent Director at Nuvectis Pharma, Inc., an Independent Director at TG Therapeutics, Inc. and a Chief Operating Officer at Stemline Therapeutics, Inc. He is on the Board of Directors at Lirum Therapeutics, Inc., Nuvectis Pharma, Inc. and TG Therapeutics, Inc. Mr. Hoberman was previously employed as a Vice President-Corporate & Business Development by Keryx Biopharmaceuticals, Inc. He received his undergraduate degree from Boston University.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
11/06/2026 279,653 ( 0.18% ) 16 M $ 30/09/2026
11/06/2026 168,140 ( 0.52% ) 4 M $ 30/09/2026

Kenneth Hoberman active positions

CompaniesPositionStart
STEMLINE THERAPEUTICS, INC. Chief Operating Officer 01/01/2013
TG THERAPEUTICS, INC. Director/Board Member 15/12/2014
NUVECTIS PHARMA, INC. Director/Board Member 01/07/2021
LIRUM THERAPEUTICS, INC. Director/Board Member 01/11/2021

Former positions of Kenneth Hoberman

CompaniesPositionEnd
KERYX BIOPHARMACEUTICALS Corporate Officer/Principal 01/01/2012
See the detail of Kenneth Hoberman's experience

Education of Kenneth Hoberman

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

51

1st degree connections

6

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies6

Health Technology

Health Technology

Health Technology

Consumer Services

Health Technology

Commercial Services

  1. Stock Market
  2. Insiders
  3. Kenneth Hoberman